- Home
- CLRB vs IGC Comparison
CLRB vs IGC Comparison
Compare CLRB & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- IGC
- Stock Information
- Founded
- CLRB 2002
- IGC 2005
- Country
- CLRB United States
- IGC United States
- Employees
- CLRB N/A
- IGC N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- IGC Health Care
- Exchange
- CLRB Nasdaq
- IGC Nasdaq
- Market Cap
- CLRB 17.6M
- IGC 20.2M
- IPO Year
- CLRB N/A
- IGC N/A
- Fundamental
- Price
- CLRB $4.98
- IGC $0.30
- Analyst Decision
- CLRB Hold
- IGC Strong Buy
- Analyst Count
- CLRB 2
- IGC 2
- Target Price
- CLRB N/A
- IGC $3.88
- AVG Volume (30 Days)
- CLRB 1.3M
- IGC 242.6K
- Earning Date
- CLRB 08-12-2025
- IGC 06-27-2025
- Dividend Yield
- CLRB N/A
- IGC N/A
- EPS Growth
- CLRB N/A
- IGC N/A
- EPS
- CLRB N/A
- IGC N/A
- Revenue
- CLRB N/A
- IGC $1,271,000.00
- Revenue This Year
- CLRB N/A
- IGC $15.26
- Revenue Next Year
- CLRB N/A
- IGC $3.41
- P/E Ratio
- CLRB N/A
- IGC N/A
- Revenue Growth
- CLRB N/A
- IGC N/A
- 52 Week Low
- CLRB $4.36
- IGC $0.25
- 52 Week High
- CLRB $94.50
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CLRB 33.34
- IGC 44.68
- Support Level
- CLRB $6.50
- IGC $0.30
- Resistance Level
- CLRB $8.30
- IGC $0.32
- Average True Range (ATR)
- CLRB 1.42
- IGC 0.01
- MACD
- CLRB -0.66
- IGC -0.00
- Stochastic Oscillator
- CLRB 1.63
- IGC 12.50
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.